Cardiometabolic Health in Older Adults: Risks, Evidence, and Clinical Priorities

Why Cardiometabolic Risk Accelerates After Age 60

The biology of aging itself drives cardiometabolic deterioration. Skeletal muscle mass falls by 3 to 8 percent per decade after age 30, and the pace doubles after 60 [1]. Less muscle means lower glucose disposal, higher fasting insulin, and rising visceral fat even when total body weight stays stable [2]. Adipokine profiles shift simultaneously: adiponectin falls while leptin and inflammatory cytokines including interleukin-6 and tumor necrosis factor-alpha rise, compounding endothelial dysfunction [3].

The numbers reflect that biology. The CDC's 2023 heart disease and stroke statistics report places 74 percent of all US cardiovascular deaths in adults aged 65 and older [4]. Metabolic syndrome, defined by the 2009 Joint Interim Statement criteria as any three of elevated waist circumference, triglycerides, reduced HDL, elevated blood pressure, or elevated fasting glucose, affects over 47 percent of adults aged 60 and older compared with roughly 22 percent in the 20-to-39 age group [5].

A large observational analysis published in JAMA Internal Medicine (N=3,742) found that each five-year increment of age above 55 was independently associated with a 12 percent higher odds of incident metabolic syndrome after adjusting for BMI, smoking, and physical activity [6]. That association held in both sexes, though the absolute prevalence gap between men and women narrowed after age 70 [6].

Clinically, this means routine cardiometabolic screening, not just lipid panels but waist circumference, fasting glucose, HbA1c, and blood pressure, should occur at every annual visit for patients over 55 regardless of symptoms.

Type 2 Diabetes in Older Adults: Diagnosis and Pharmacotherapy

Type 2 diabetes touches approximately 29 percent of Americans aged 65 and older, and an additional 48 percent of that age group has prediabetes [7]. Diagnosis in older patients can be delayed because classic polyuria and polydipsia may be blunted by age-related reduction in thirst perception and renal glucose threshold [8].

The American Diabetes Association's 2024 Standards of Care recommend an HbA1c target of 7.0 to 7.5 percent for most healthy older adults, relaxed to 8.0 to 8.5 percent for those with multiple comorbidities, frailty, or limited life expectancy [9]. Hypoglycemia in older patients is not merely uncomfortable. A prospective analysis from the ACCORD trial showed that each severe hypoglycemic episode was associated with a 1.79-fold higher risk of subsequent dementia in patients aged 55 and older [10].

Metformin remains first-line for most older patients with an eGFR at or above 30 mL/min/1.73m2 [9]. For patients with established atherosclerotic cardiovascular disease or heart failure, SGLT-2 inhibitors and GLP-1 receptor agonists carry Class I evidence. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 14 percent versus placebo in patients with T2DM and established CVD [11]. The LEADER trial (N=9,340) showed liraglutide reduced the same composite by 13 percent [12].

Dose adjustment matters more in older patients. Renal function declines approximately 1 mL/min/1.73m2 per year after age 40, and many older patients reach SGLT-2 dose-reduction thresholds without any GFR-flagging symptom [8].

GLP-1 Receptor Agonists: Efficacy and Safety Considerations in Aging Patients

GLP-1 receptor agonists are now first-line agents for cardiovascular risk reduction in T2DM and for chronic weight management, but their use in older adults requires specific attention to muscle mass, renal function, and gastrointestinal tolerability.

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9 percent mean body-weight loss at 68 weeks versus 2.4 percent with placebo (P<0.001) [13]. A pre-specified subgroup analysis of STEP-1 participants aged 65 and older showed similar relative weight loss, roughly 13.8 percent, but a higher incidence of dehydration-related adverse events (8.3% vs. 3.1% in younger participants) [13].

Sarcopenic obesity, excess fat combined with low muscle mass, is common in older adults and complicates GLP-1 use. Weight lost on semaglutide is approximately 38 percent lean mass when resistance exercise is not prescribed concurrently [14]. For older patients this ratio is clinically meaningful because muscle loss worsens fall risk and insulin resistance simultaneously. The recommended mitigation is concurrent resistance training at least two days per week plus protein intake at or above 1.2 g/kg body weight per day [14].

Tirzepatide, a dual GIP/GLP-1 agonist, produced 20.9 percent mean weight loss in the SURMOUNT-1 trial (N=2,539) at the 15 mg dose over 72 weeks [15]. Cardiovascular outcome data in older cohorts are pending the SURPASS-CVOT results, expected in 2025.

The FDA label for semaglutide (Wegovy) notes no dose adjustment required for age alone, but renal and hepatic function should be assessed at baseline and every 6 months in patients aged 70 and older [16].

Cardiometabolic Health in Women: Menopause, HRT, and Risk Stratification

Women experience a sharp upward inflection in cardiometabolic risk at menopause, driven by estrogen withdrawal, central fat redistribution, and worsening lipid profiles [17]. LDL cholesterol rises by an average of 10 to 14 mg/dL within two years of the final menstrual period, and HDL cholesterol falls by 3 to 5 mg/dL over the same interval [17].

The original Women's Health Initiative (WHI) 2002 publication created lasting confusion by reporting increased cardiovascular events with combined estrogen-progestin therapy, but the study enrolled women at a mean age of 63, more than a decade past average menopause [18]. The "timing hypothesis," supported by re-analyses and the KEEPS trial (N=727), holds that hormone therapy started within 10 years of menopause onset does not increase and may reduce coronary artery disease risk [19].

The Menopause Society 2022 position statement reads: "For women who are within 10 years of menopause onset or under age 60 and have no contraindications, the benefits of hormone therapy outweigh the risks for treatment of bothersome vasomotor symptoms and for prevention of bone loss" [20]. That statement explicitly acknowledges the cardiovascular nuance of the timing hypothesis [20].

Thyroid dysfunction adds another layer of cardiometabolic risk in women. Hypothyroidism, present in 5 to 8 percent of women over 50, raises LDL, lowers heart rate, and increases diastolic blood pressure [21]. Subclinical hypothyroidism (TSH 4.5 to 10 mIU/L with normal free T4) in women over 65 was associated with a 65 percent higher risk of heart failure hospitalization in a meta-analysis of 6 prospective studies (N=25,977) [21].

A practical HealthRX cardiometabolic screening sequence for women at menopause transition: fasting lipid panel, fasting glucose plus HbA1c, TSH, blood pressure on two separate occasions, waist circumference, and 10-year ASCVD risk calculation using the Pooled Cohort Equations. Repeat annually. Initiate statin therapy if 10-year risk exceeds 7.5 percent per 2019 ACC/AHA guidelines [22].

Gestational Diabetes: Cardiometabolic Risk Across the Lifespan

Gestational diabetes mellitus (GDM) affects 5 to 9 percent of US pregnancies and is not simply a transient pregnancy complication [23]. It is a cardiometabolic stress test that identifies women at high future risk.

A meta-analysis in The Lancet (N=675,455 women) found that a history of GDM was associated with a 7.76-fold higher relative risk of developing type 2 diabetes later in life compared with women with normoglycemic pregnancies [24]. Cardiovascular risk also rises: GDM history was associated with a 2.0-fold higher risk of premature cardiovascular disease in a Danish registry cohort of 1.3 million women followed for up to 18 years [25].

During pregnancy, management targets are fasting glucose below 95 mg/dL and one-hour postprandial glucose below 140 mg/dL per the American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 190 [23]. Insulin is the only medication FDA-approved for GDM, though metformin is sometimes used off-label [23].

GLP-1 receptor agonists including semaglutide and tirzepatide are contraindicated in pregnancy. Women of reproductive age on these agents should use effective contraception and discontinue the drug at least two months before a planned conception, per FDA labeling [16]. Animal reproductive toxicity data show fetal growth restriction and structural malformations at clinically relevant exposures [16].

After delivery, ACOG recommends a 75 g oral glucose tolerance test at 4 to 12 weeks postpartum and then HbA1c or fasting glucose every 1 to 3 years for life [23]. In practice, fewer than 50 percent of women complete even the first postpartum screening [26].

Cardiometabolic Disease in Diabetes: Beyond Glucose Control

Cardiovascular disease is the primary cause of death in people with type 2 diabetes, accounting for approximately 50 percent of all-cause mortality in that population [27]. Achieving glycemic targets alone does not fully explain cardiovascular outcomes. The UKPDS 10-year follow-up showed that intensive glucose control during the active trial phase reduced myocardial infarction by 15 percent and all-cause mortality by 13 percent in the post-trial period, a "legacy effect" [28].

Blood pressure control matters as much as glucose. The HOT trial and subsequent JNC guidelines established that systolic blood pressure below 130 mmHg in patients with diabetes reduces stroke risk by roughly 40 percent compared with less intensive targets [29]. The 2017 ACC/AHA hypertension guidelines now recommend a target below 130/80 mmHg for adults with diabetes and CVD or 10-year ASCVD risk at or above 10 percent [29].

Lipid management in diabetes follows the same 2019 ACC/AHA framework. All adults with T2DM aged 40 to 75 with LDL 70 to 189 mg/dL should receive at least moderate-intensity statin therapy; those with 10-year ASCVD risk at or above 20 percent should receive high-intensity statin plus consideration of ezetimibe or a PCSK9 inhibitor [22].

The combination of statin, ACE inhibitor or ARB, and either an SGLT-2 inhibitor or GLP-1 agonist in patients with established ASCVD plus T2DM reduces 3-point MACE by an estimated 35 to 40 percent compared with glucose-only management, based on pooled cardiovascular outcomes trial data [11][12].

Testosterone, Cardiometabolic Risk, and Older Men

Testosterone levels fall by roughly 1 to 2 percent per year after age 30 in men, and hypogonadism, defined as total testosterone below 300 ng/dL with consistent symptoms, is present in approximately 20 to 30 percent of men over 60 [30]. Low testosterone is independently associated with insulin resistance, metabolic syndrome, and higher visceral fat mass [30].

The TRAVERSE trial (N=5,246, mean age 63.5 years), published in the New England Journal of Medicine in 2023, was the landmark cardiovascular safety study for testosterone replacement therapy (TRT) in men with hypogonadism and either established CVD or elevated CV risk [31]. Over a median follow-up of 33 months, testosterone therapy was non-inferior to placebo for the primary composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke (hazard ratio 0.96 to 95% CI 0.78 to 1.17) [31]. The trial did find higher rates of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone arm [31].

The Endocrine Society 2018 clinical practice guideline states: "We recommend against starting testosterone therapy in patients with cardiovascular disease until the benefit/risk ratio is better defined" [32]. TRAVERSE has now provided much of that definition, though the atrial fibrillation signal warrants shared decision-making with older patients who already carry AF risk factors [31].

From a cardiometabolic standpoint, TRT in hypogonadal men does reduce HbA1c by approximately 0.4 percent and waist circumference by 3.2 cm on average in randomized trial meta-analyses, suggesting modest metabolic benefit alongside the non-inferior cardiovascular safety profile [30].

Cardiometabolic Health in Aging Athletes

Older competitive athletes present a paradox. They carry far lower cardiometabolic risk than sedentary peers in most metrics, yet lifelong high-volume endurance training is associated with a higher prevalence of coronary artery calcification and atrial fibrillation [33].

The Copenhagen City Heart Study (N=5,000+, followed for up to 35 years) found that light to moderate jogging, defined as 1 to 2.4 hours per week at a slow to moderate pace, was associated with the lowest all-cause mortality. Strenuous joggers fared no better than sedentary individuals in that specific cohort, though absolute mortality was still lower than the general population [34].

For the typical older adult exerciser, the evidence is uniformly positive. A meta-analysis in the Journal of the American College of Cardiology (46 randomized trials, N=12,795) showed that structured exercise training reduced cardiovascular mortality by 26 percent and all-cause mortality by 15 percent in patients with established coronary heart disease [35]. Resistance training two to three times per week reduces HbA1c by 0.34 percent independent of aerobic training in adults with T2DM, per a Cochrane review of 14 trials [36].

For masters athletes aged 65 and older returning to vigorous training after a cardiac event, a graded exercise stress test to at least 85 percent of age-predicted maximum heart rate is recommended before clearance, per the American Heart Association's 2014 scientific statement on exercise standards [37]. Resting 12-lead ECG, echocardiogram if structural disease is suspected, and baseline lipid and glucose panel round out the pre-participation workup.

The cardiometabolic sweet spot in older adults appears to be 150 to 300 minutes per week of moderate-intensity aerobic activity combined with two to three sessions of resistance training, consistent with the 2018 Physical Activity Guidelines for Americans [38]. That dose reduces 10-year ASCVD risk by approximately 35 percent in cohort modeling studies [38].

Statin Therapy in Adults Over 75: Evidence and Controversy

Adults over 75 were largely excluded from the original statin cardiovascular outcome trials, leaving a genuine evidence gap for primary prevention in this age group. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease recommends that clinicians engage in a risk-benefit discussion before initiating statin therapy in adults over 75 for primary prevention, noting that net benefit is less certain than in younger cohorts [22].

For secondary prevention, the data are clearer. The Cholesterol Treatment Trialists' (CTT) meta-analysis (174,000 participants, 27 trials) found that each 1.0 mmol/L reduction in LDL with statin therapy reduced major vascular events by 21 percent regardless of age subgroup, including patients over 75 [39]. The number needed to treat to prevent one major vascular event over 5 years was approximately 25 in high-risk older patients [39].

Statin-associated muscle symptoms (SAMS) occur in 5 to 10 percent of patients overall but rise to 15 to 20 percent in adults over 70, partly due to polypharmacy interactions [40]. CK measurement at baseline and a structured symptom diary improve detection. Switching to rosuvastatin 5 to 10 mg or pravastatin 40 mg, both hydrophilic agents with lower muscle penetration, reduces SAMS rates while preserving LDL-lowering efficacy [40].